AIDS Day, Johnson & Johnson launches HIV vaccine key trial
AIDS Day, Johnson & Johnson launches HIV vaccine key trial
December 01, 2017 Source: WuXi PharmaTech
Window._bd_share_config={ "common":{ "bdSnsKey":{ },"bdText":"","bdMini":"2","bdMiniList":false,"bdPic":"","bdStyle":" 0","bdSize":"16"},"share":{ }};with(document)0[(getElementsByTagName('head')[0]||body).appendChild(createElement('script')) .src='http://bdimg.share.baidu.com/static/api/js/share.js?v=89860593.js?cdnversion='+~(-new Date()/36e5)];December 1st is World AIDS Day. Today, Johnson & Johnson announced the launch of its first research on the efficacy of a chimeric HIV-1 prophylactic vaccine with its global partners to assess the vaccine's ability to prevent HIV in 2,600 African women.
Humankind has made significant progress in the global fight against AIDS, including the development of key antiretroviral therapies and HIV prevention tools, but the disease remains one of the current serious global health threats. There are currently 37 million HIV-infected people worldwide, with nearly 2 million new infections each year. Prevention of HIV infection is the main way to control the spread of disease, but due to the unique nature of HIV, including complex genetic diversity and rapid mutation, resulting in too many viral subtypes around the world, effective HIV vaccines have not yet obtain.
To solve this problem, Johnson & Johnson's researchers put together multiple genes from various viral subtypes to find a complex profile to create a "global" vaccine that can be used around the world. The HIV-1 prophylactic vaccine program utilizes Janssen's AdVac® adenoviral vector platform and PER.C6® production cell line technology, and consists of four components (tetravalent) chimeric adenovirus serotype 26 vector (Ad26.Mos4). .HIV) and soluble protein composition. In preclinical studies, the vaccine showed 66% efficiency in non-primate animals. The results of the 1/2 phase study published earlier this year showed that the vaccine elicited an antibody response in 100% of the study participants.
Based on these excellent results, this large-scale proof-of-concept study called Imbokodo (HVTN705/HPX2008) was launched in southern Africa at the end of this year. The trial will recruit 2,600 women aged 18-35 from five countries in southern Africa. In this region, female HIV-infected people account for 60%. The researchers tracked these volunteers for 2 years to further validate the persistence of the vaccine. If the situation is ideal, it may take five years to use the AIDS vaccine globally.
â–² Dr. Paul Stoffels, Chief Scientific Officer of Johnson & Johnson (Source: Johnson & Johnson)
“Developing a vaccine against HIV is a top priority and our greatest hope for eliminating AIDS. Finding an effective AIDS vaccine to protect high-risk groups has always been a major scientific challenge, but today we are optimistic that it can be achieved,†Johnson & Johnson Dr. Paul Stoffels, Chief Scientific Officer of the company, said: "This is why we are working with the world's leading AIDS researchers and global health advocates to promote our ongoing vaccines. We work together to achieve the ultimate goal of making AIDS a thing of the past."
“Imbokodo's public and private collaborative research is dedicated to the powerful and terrible HIV virus,†said Professor Glenda Gray, CEO and President of the South African Medical Research Council and Chairman of the Imbokodo Study. “Africa's Leadership in Ending the Epidemic It is documented in its groundbreaking scientific research, and its contribution to the people is also evident."
“Preventive vaccines will be an important tool for a comprehensive global strategy to eradicate the HIV epidemic,†said Dr. Johan Van Hoof, Head of Infectious Diseases and Vaccine Development at Janssen. “Our research vaccines are based on the use of different HIV subtypes. The genetically engineered chimeric antigen. The ultimate goal is to provide a "global" vaccine that can be used in any region to help protect high-risk populations susceptible to infection."
Today is World AIDS Day. On this special day, this news shows us that human beings are a step closer to fighting AIDS. Thanks to the contributions of the researchers, we look forward to the day when AIDS is conquered.
Reference materials:
[1] J&J-led coalition launches a landmark efficacy study for an HIV mosaic vaccine
[2] J&J, Gates Foundation and NIAID launch efficacy study for their 'global' HIV vaccine
[3] Janssen Official Website
[4] Courier | The first human clinical study, Johnson & Johnson HIV vaccine received gratifying data
Maitake Mushroom Extract;edible mushroom extract
Shaanxi Zhongyi Kangjian Biotechnology Co.,Ltd , https://www.zhongyiherbs.com